批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2023/08/09 |
SUPPL-5(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2023/08/09 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/04/27 |
ORIG-1(原始申请) |
Approval |
|
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
无 |
与本品治疗等效的药品
活性成分:PHENYLEPHRINE HYDROCHLORIDE 剂型/给药途径:SOLUTION;INTRAVENOUS 规格:10MG/ML (10MG/ML) 治疗等效代码:AP2
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
203826 |
001 |
NDA |
PHENYLEPHRINE HYDROCHLORIDE |
PHENYLEPHRINE HYDROCHLORIDE |
SOLUTION;INTRAVENOUS |
10MG/ML (10MG/ML) |
Prescription |
Yes |
Yes |
AP2 |
2012/12/20
|
HIKMA |
210334 |
001 |
ANDA |
PHENYLEPHRINE HYDROCHLORIDE |
PHENYLEPHRINE HYDROCHLORIDE |
SOLUTION;INTRAVENOUS |
10MG/ML (10MG/ML) |
Prescription |
No |
No |
AP2 |
2018/04/27
|
MEITHEAL |
210665 |
001 |
ANDA |
PHENYLEPHRINE HYDROCHLORIDE |
PHENYLEPHRINE HYDROCHLORIDE |
SOLUTION;INTRAVENOUS |
10MG/ML (10MG/ML) |
Prescription |
No |
No |
AP2 |
2019/01/29
|
FRESENIUS KABI USA |
210696 |
001 |
ANDA |
PHENYLEPHRINE HYDROCHLORIDE |
PHENYLEPHRINE HYDROCHLORIDE |
SOLUTION;INTRAVENOUS |
10MG/ML (10MG/ML) |
Prescription |
No |
No |
AP2 |
2021/01/07
|
EUGIA PHARMA |
209968 |
001 |
ANDA |
PHENYLEPHRINE HYDROCHLORIDE |
PHENYLEPHRINE HYDROCHLORIDE |
SOLUTION;INTRAVENOUS |
10MG/ML (10MG/ML) |
Prescription |
No |
No |
AP2 |
2023/02/28
|
AVET LIFESCIENCES |
217521 |
001 |
ANDA |
PHENYLEPHRINE HYDROCHLORIDE |
PHENYLEPHRINE HYDROCHLORIDE |
SOLUTION;INTRAVENOUS |
10MG/ML (10MG/ML) |
Prescription |
No |
No |
AP2 |
2023/06/26
|
BE PHARMS |